SEC Company Response from ReShape Lifesciences Inc. (RSLS) (CIK 0001427570) (HIND) — Nov 17, 2017
ReShape Lifesciences Inc. (RSLS) (CIK 0001427570)
Date: Nov. 17, 2017 · CIK: 0001427570 · Accession: 0001628280-17-011660
AI Filing Summary & Sentiment
File numbers found in text: 333-221264
Letter
VIA EDGAR Washington, D.C. 20549 Attn: Heather Percival Re: Obalon Therapeutics, Inc. Registration Statement on Form S-3 Filed November 1, 2017 File No. 333-221264
Dear Ms. Percival:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, Obalon Therapeutics, Inc., a Delaware corporation (the “Registrant”), hereby requests acceleration of the effective date of the Registration Statement referred to above so that it may become effective at 5:00 p.m. Eastern Standard Time on November 17, 2017, or as soon thereafter as practicable.
We acknowledge the following:
•
should the U.S. Securities and Exchange Commission (the “Commission”) or its staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
•
the Registrant may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
We appreciate your assistance in this matter.
Securities and Exchange Commission
November 17, 2017
Page 2
Very truly yours,
OBALON THERAPEUTICS, INC.,
a Delaware corporation
Show Raw Text
CORRESP 1 filename1.htm Document Obalon Therapeutics, Inc. 5421 Avenida Encinas, Suite F Carlsbad, CA 92008 November 17, 2017 VIA EDGAR The Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Heather Percival Re: Obalon Therapeutics, Inc. Registration Statement on Form S-3 Filed November 1, 2017 File No. 333-221264 Dear Ms. Percival: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, Obalon Therapeutics, Inc., a Delaware corporation (the “Registrant”), hereby requests acceleration of the effective date of the Registration Statement referred to above so that it may become effective at 5:00 p.m. Eastern Standard Time on November 17, 2017, or as soon thereafter as practicable. We acknowledge the following: • should the U.S. Securities and Exchange Commission (the “Commission”) or its staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; • the action of the Commission or staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and • the Registrant may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We appreciate your assistance in this matter. Securities and Exchange Commission November 17, 2017 Page 2 Very truly yours, OBALON THERAPEUTICS, INC., a Delaware corporation By: /s/ William Plovanic Name: William Plovanic Title: Chief Financial Officer cc: B. Shayne Kennedy, Esq., Latham & Watkins LLP